State of Alaska Department of Revenue Sells 100,365 Shares of Bristol-Myers Squibb (NYSE:BMY)

State of Alaska Department of Revenue decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 21.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 362,632 shares of the biopharmaceutical company’s stock after selling 100,365 shares during the period. State of Alaska Department of Revenue’s holdings in Bristol-Myers Squibb were worth $20,510,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Algert Global LLC bought a new stake in Bristol-Myers Squibb during the second quarter worth about $328,000. AMF Tjanstepension AB lifted its position in Bristol-Myers Squibb by 6.9% during the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after buying an additional 39,419 shares in the last quarter. Czech National Bank grew its holdings in Bristol-Myers Squibb by 6.9% during the 3rd quarter. Czech National Bank now owns 413,002 shares of the biopharmaceutical company’s stock worth $21,369,000 after acquiring an additional 26,718 shares during the last quarter. Callan Family Office LLC bought a new position in shares of Bristol-Myers Squibb in the third quarter worth about $238,000. Finally, Chesley Taft & Associates LLC grew its stake in shares of Bristol-Myers Squibb by 5.0% during the third quarter. Chesley Taft & Associates LLC now owns 5,250 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 252 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on BMY. Bank of America reaffirmed a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Cantor Fitzgerald upped their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Finally, BMO Capital Markets increased their target price on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $56.93.

Bristol-Myers Squibb Stock Up 0.9 %

Shares of BMY stock opened at $59.66 on Thursday. The firm’s fifty day moving average price is $57.64 and its two-hundred day moving average price is $53.59. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm has a market capitalization of $121.01 billion, a P/E ratio of -16.62, a PEG ratio of 2.10 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. On average, equities analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.16%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.